Clinical Trials Sponsored by Novartis+Pharmaceuticals

Total 21562 results

Novartis Pharmaceuticals

Active, not recruiting

Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects (CCFZ533X2207)

Type 1 Diabetes Mellitus

Belgium, Italy, Spain, United Kingdom, Germany, Slovenia
Novartis Pharmaceuticals

Terminated

Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM

Obesity

United States
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. (V-Mono China)

Primary Hypercholesterolemia or Mixed Dyslipidemia

China
Novartis Pharmaceuticals

Active, not recruiting

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA

Osteoarthritis (OA)

Netherlands
Novartis Pharmaceuticals

Active, not recruiting

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Myelodysplastic Syndrome (MDS)

United States
Novartis Pharmaceuticals

Active, not recruiting

Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment (AgAIN)

Psoriatic Arthritis

Germany
Novartis Pharmaceuticals

Completed

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

Chronic Spontaneous Urticaria

Spain, Germany, France, Korea, Republic of, Turkey, Argentina, Slovakia, United States, Canada, Singapore
Novartis Pharmaceuticals

Active, not recruiting

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis (OLIKOS)

Relapsing Multiple Sclerosis

United States, Puerto Rico
Novartis Pharmaceuticals

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

Progressive Supranuclear Palsy (PSP)

Germany, United Kingdom, Canada, United States
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

Relapsing Multiple Sclerosis

China
Novartis Pharmaceuticals

Completed

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1- Antihistamines (REMIX-2)

Chronic Spontaneous Urticaria

United States, India, Malaysia, Taiwan, Poland, United Kingdom, China, Thailand, Switzerland, Germany, Vietnam, Brazil, Russian Federation, Slovakia, Denmark, Canada, South Africa, Austria
Novartis Pharmaceuticals

Active, not recruiting

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Belgium, Italy, Korea, Republic of, Hong Kong, Israel, Finland, Spain, Japan, United States
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Hematologic Diseases | Chronic Myelogenous Leukemia | CML | Leukemia, Myeloid Chronic

Taiwan, Italy, Spain, United Kingdom, Germany, United States, Korea, Republic of, France, Russian Federation, Canada, Denmark, Poland, Portugal, Austria, Czechia
Novartis Pharmaceuticals

Completed

Study of Diagnostic Performance of [18F]CTT1057 in BCR (GuidePath)

Recurrence | Prostatic Neoplasms | Prostate Cancer

Spain, France, Switzerland, United States
Novartis Pharmaceuticals

Active, not recruiting

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE)

Myelofibrosis

United Kingdom, Australia, Canada, Switzerland, Netherlands, Spain, Germany, Italy, Turkey, Russian Federation, Sweden, Denmark, Hungary
Novartis Pharmaceuticals

Active, not recruiting

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

United States, China, Hungary, Japan, Belgium, Germany, Canada, Singapore, Australia, Israel, Netherlands, Spain, Italy, Korea, Republic of, Bulgaria, France, United Kingdom, Czechia, Sweden, India, Malaysia, Denmark, Taiwan, Norway, Fi... and more
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN)

IgA Nephropathy

United States, Taiwan, Czechia, Germany, Hungary, India, Turkey, Belgium, Netherlands, Singapore, Australia, Canada, Italy, Korea, Republic of, Spain, Thailand, Denmark, Slovenia, United Kingdom, Argentina, Brazil, Israel, Japan, France, Swed... and more
Novartis Pharmaceuticals

Active, not recruiting

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients (STAND)

Sickle Cell Disease (SCD)

United States, United Kingdom, Germany, Spain, Greece, Italy, Brazil, Lebanon, Turkey, Belgium, France, Jordan, India, Finland, Canada, Colombia, Netherlands, Oman, South Africa, Panama, Ghana
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Chronic Myelogenous Leukemia

United States, United Kingdom, Hungary, Japan, Saudi Arabia, Australia, Germany, Canada, France, Netherlands, Spain, Lebanon, Turkey, Korea, Republic of, Argentina, Brazil, Bulgaria, Czechia, Israel, Italy, Mexico, Romania, Russian... and more
Novartis Pharmaceuticals

Temporarily not available

Managed Access Programs for LEE011, Ribociclib

Breast Cancer
Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

Treatment-Resistant Depression

Spain, Japan, Poland, United States
Novartis Pharmaceuticals

Completed

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. (IMAGINE)

Neovascular Age-related Macular Degeneration

Italy
Novartis Pharmaceuticals

Completed

CLCZ696B2319E1 OL Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Heart Failure

United States, Italy, Croatia, India, Japan, Poland, Spain, Taiwan, Austria, Korea, Republic of, Germany, Lebanon, Thailand, Canada, Bulgaria, Russian Federation, Turkey, Switzerland, Argentina, Hungary, Portugal, Finland, South Africa and more
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines (BISCUIT)

Chronic Spontaneous Urticaria

Japan
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis (ONWARDS)

Osteoarthritis

Taiwan, Spain, United Kingdom, United States, Argentina, Australia, Denmark, India, China, Czechia, Canada, Japan, Poland, Mexico, Estonia
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients (DRAGON)

Migraine

China, Taiwan, Korea, Republic of, Thailand, India, Singapore, Malaysia, Philippines, Vietnam
Novartis Pharmaceuticals

Completed

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

Transfusion-dependent Anemia

Egypt, Hungary, Turkey, United States, Bulgaria, Italy, Belgium, Russian Federation, Philippines, France, Malaysia, India, Oman, Panama, Lebanon, Thailand, Tunisia
Novartis Pharmaceuticals

Completed

Special Drug Use-results Surveillance of Scemblix Tablets

Chronic Myeloid Leukemia

Japan
Novartis Pharmaceuticals

Completed

Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions (ADITION)

Asthma

Germany
Novartis Pharmaceuticals

Completed

Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support (SPIRIT)

Atherosclerotic Cardiovascular Disease | Atherosclerotic Cardiovascular Disease Risk Equivelents | Elevated Low Density Lipoprotein Cholesterol

United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Non-Hodgkin Lymphoma

Spain, Taiwan, Australia, Belgium, Germany, Italy, Singapore, Austria, France, Switzerland, Hong Kong, United States, Netherlands, Norway, United Kingdom, Brazil, China, Japan
Novartis Pharmaceuticals

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

China
Novartis Pharmaceuticals

Active, not recruiting

A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China

Moderate to Severe Chronic Plaque Psoriasis

China
Novartis Pharmaceuticals

Completed

A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China (UNMASK2)

Psoriasis

China
Novartis Pharmaceuticals

Completed

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

Belgium, Spain, Russian Federation, Germany, United States, Czechia, Peru, Poland, Estonia
Novartis Pharmaceuticals

Active, not recruiting

A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study

Heart Failure

Japan
Novartis Pharmaceuticals

Available

MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Polycythemia Vera
Novartis Pharmaceuticals

Active, not recruiting

A Study of WVT078 in Patients With Multiple Myeloma (MM)

Multiple Myeloma (MM)

United States, Italy, Israel, Germany, Japan, Spain, Australia, Norway
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KITE)

Diabetic Macular Edema

Czechia, India, Russian Federation, Taiwan, Turkey, Lebanon, Denmark, Estonia, France, Germany, Hungary, Korea, Republic of, Latvia, Lithuania, Bulgaria, Norway, Belgium, Malaysia, Sweden, Slovakia, Singapore, Poland, Switzerland
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function (ELTION)

Poor Graft Function

Spain
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3)

Triple Negative Breast Neoplasms

France, Italy, Croatia, Taiwan, Australia, Argentina, Korea, Republic of, China, Israel, Russian Federation, Slovakia, Slovenia, United Kingdom, Germany, Mexico, Switzerland, Spain, Brazil, Hungary, Malaysia, South Africa, Austria, ... and more
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA) (STEER)

Type 2 Spinal Muscular Atrophy

United States, China, Saudi Arabia, Thailand, Singapore, Brazil, Malaysia, Taiwan, Colombia, Mexico, Denmark, Egypt, India, South Africa, Vietnam
Novartis Pharmaceuticals

Completed

Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.

Diffuse Large B-cell Lymphoma

United States
Novartis Pharmaceuticals

Completed

Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients

Secondary Progressive Multiple Sclerosis (SPMS)

Japan
Novartis Pharmaceuticals

Completed

Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma

BRAF-positive Metastatic Melanoma

United States
Novartis Pharmaceuticals

Available

Managed Access Programs for INC424, Ruxolitinib

Primary Myelofibrosis (PMF) | Polycythemia Vera (PV) | Post Polycythemia Myelofibrosis (PPV MF) | Thrombocythemia Myelofibrosis (PET-MF) | Severe/Very Severe COVID-19 Illness | Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) | Steroid Refractory Chronic Graft Versus Host Disease...
Novartis Pharmaceuticals

Available

Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell Lung | Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals

Available

Managed Access Program (MAP) to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

PIK3CA-Related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals

Completed

A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease (VIBRANT-HD)

Early Manifest Huntington Disease

Canada, Germany, France, Spain, Hungary
Novartis Pharmaceuticals

Completed

Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study (APOLLON)

Migraine | Migraine Disorders | Migraine Headache

Germany

Clinical Trials Sponsored by Novartis+Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations